Apr 20, 2022
Drug pricing is one of the hottest topics in the healthcare segment. Several arguments have been put forward by people, governments, healthcare companies, and other organizations in favor of and against expensive medicines. Some of the drugs are so expensive that they are nearly out of reach of the common people. H...
Read More...
Apr 19, 2022
GSK Acquires Sierra Oncology for USD 1.9 Billion GlaxoSmithKline has agreed to buy Sierra Oncology and its lead drug assets, momelotinib, for anemia caused by the blood malignancy myelofibrosis. GSK is paying USD 55 per share in cash for Sierra, a 39% premium to the company's closing share price yesterday, valui...
Read More...
Apr 18, 2022
Post Lumakras ‘approval, Adagrasib’s PDUFA date, Novartis now ready to enter the KRASG12C space Novartis is now heading towards its unique KRASG12C inhibitor in patients with advanced non-small cell lung cancer (NSCLC). The company presented the promising preliminary data (Phase Ib) from the KontRASt-01 study e...
Read More...
Apr 18, 2022
An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery. Most Intraocular Lenses (IOL) are made of silicone, acrylic, or other plastic compositions and are also coated w...
Read More...
Apr 18, 2022
TIGIT (T cell immunoreceptor with Ig and ITIM domains) - The red hot corner of immune-oncology market drawing huge Interest Interest in TIGIT has increased since last 2-3 years and several key players are now active in this field including BeiGene’s Ociperlimab, which is in Phase III stage of development fo...
Read More...
Apr 15, 2022
Glaucoma is a group of progressive optic neuropathy which is characterized by the degradation of ganglion cells present in the retina. The loss of the retinal ganglion is associated with intraocular pressure (IOP), an elevated IOP due to an imbalance in the production and drainage of aqueous humor that might lead t...
Read More...
Apr 14, 2022
Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022. The data demonstrated that the tetravalent and unique structure of FS118 played a ...
Read More...
Apr 14, 2022
Alcon Announces Launch of Dry Eye Treatment Device On April 04, 2022, Alcon Inc. announced the launch of their latest dry eye innovation, the Systane® iLux2® Meibomian Gland Dysfunction (MGD) Thermal Pulsation System. It is an all-in-one handheld device equipped with new imaging technology to capture infrared ph...
Read More...
Apr 13, 2022
The metaverse, or Internet 3.0, is an evolution of how individuals can socially connect with each other despite geographical distance and regional boundaries. Metaverse is set to bring a disruptive revolution in various aspects of life, including healthcare. For many decades, the delivery of healthcare has required...
Read More...
Apr 12, 2022
FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Disorder. Igalmi (dexmedetomidine) is the first drug approved for this application that comes in the form of a tablet that...
Read More...